Australian Cell Graft For Nervous System Gets Funding Boost

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Griffith University, based in Australia, has gone on to conduct a world-first study when it comes to cell transplantation so as to repair nervous system injuries and has thus received a tremendous boost of a $5.4 million fund extension from the Motor Accident Insurance Commission.

Professor James St. John, who happens to head the Griffith’s Clem Jones Centre for Neurobiology and Stem Cell Research, has confirmed that they are coming up with cell transplantation therapies in order to treat injuries that are related to the nervous system.

The research team, under the guidance of Professor John, has gone on to develop a world-first cellular nerve bridge, which has already received a couple of major national awards, namely the NHMRC Marshall and Warren Innovation Award for 2019 and the Research Australia Discovery Award for 2020–21.

The latest round of funding is going to allow the research team at Griffith to expand the horizons of the nerve build technology to a range of nervous system injuries that happen to be wider, including brain as well as peripheral nerve injuries.

It is well to be noted that the new MAIC funding, which will be worth $5.4 million, will add up to a total investment from MAIC to the tune of $16 million since 2017, with the prime focus being on the development of a therapy related to spinal cord injury.

Latest stories

Related stories

China Unveils Innovative Drugs Policy to Boost Development

The National Health Commission and China's National Healthcare Security...

Ensuring optimal product integrity with pharmaceutical preservation strategies

Preserving the potency of pharmaceutical products is paramount in...

How Stem Cell Therapy Works for the Individual

Stem cell therapy has emerged as one of the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back